AbbVie
Trade AbbVie 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About ABBV
AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions.
ABBV Key Statistics
Stock Snapshot
AbbVie(ABBV) stock is priced at $220.06, giving the company a market capitalization of 396.12B. It carries a P/E multiple of 166.06 and pays a dividend yield of 3.0%.
As of 2026-01-13, AbbVie(ABBV) stock has fluctuated between $218.39 and $222.49. The current price stands at $220.06, placing the stock +0.8% above today's low and -1.1% off the high.
The AbbVie(ABBV)'s current trading volume is 6.55M, compared to an average daily volume of 6.41M.
In the last year, AbbVie(ABBV) shares hit a 52-week high of $244.81 and a 52-week low of $164.39.
In the last year, AbbVie(ABBV) shares hit a 52-week high of $244.81 and a 52-week low of $164.39.
ABBV News
If you are wondering whether AbbVie’s current share price reflects its underlying value, you are not alone. This article will walk through what the market might...
AbbVie also plans to expand direct-to-patient offerings through the government portal TrumpRx for some medicines. Clodagh Kilcoyne/Reuters AbbVie ABBV -0.02 %d...
AbbVie (ABBV) announced a voluntary agreement with the Trump administration to further advance access and affordability for Americans while protecting and inves...
Analyst ratings
65%
of 31 ratingsMore ABBV News
Abbvie (ABBV) announced an update on their ongoing clinical study. Claim 70% Off TipRanks Premium Study Overview: AbbVie is running a Phase 2 trial called “Mu...
Claim 70% Off TipRanks Premium An update from RemeGen Co. Ltd. Class H ( (HK:9995) ) is now available. RemeGen Co., Ltd. has signed an exclusive global licens...
AbbVie (ABBV) and RemeGen announced an exclusive licensing agreement for the development, manufacturing and commercialization of RC148, a novel investigational...
(RTTNews) - West Pharmaceutical Services, Inc. (WST) on Monday said it has agreed to sell all manufacturing and supply rights for its SmartDose 3.5mL On-Body De...
AbbVie (ABBV) and West Pharmaceutical (WST) announced a definitive agreement for AbbVie to acquire a device manufacturing facility in Tempe, Arizona and associa...
STAT’s Adam Feuerstein said viax that, “$RVMD – I had a meeting scheduled with the CEO on Monday morning. The company just cancelled. #JPM26 RevMed is also sche...
AbbVie ABBV generates a substantial portion of its revenues from its immunology franchise, driven by the encouraging uptake of its two blockbuster drugs — Skyri...